April 30, 2018 10:19 AM EDT
News Briefing

Two biotechs hunt $175 mil­lion in Nas­daq pur­suit; Keryx CEO Gre­go­ry Madi­son abrupt­ly re­signs; Rx­Cel­er­ate buys bio­an­a­lyt­i­cal CRO

John Carroll

Editor & Founder

→ Less than four months af­ter reap­ing $47 mil­lion in Se­ries C fi­nanc­ing, Schol­ar Rock is out for a $75 mil­lion IPO. The Cam­bridge …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

Co­herus makes fi­nal, $483M piv­ot away from biosim­i­lars

GSK ter­mi­nates Phase 2 tri­al of HBV ther­a­peu­tic vac­cine

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

A service from the Financial Times